Cost of oral cholera vaccine delivery in a mass immunization program for children in urban Bangladesh
Abdur Razzaque Sarker,
Ashraful Islam Khan,
Md. Taufiqul Islam,
Fahima Chowdhury,
Farhana Khanam,
Sophie Kang,
Faisal Ahmmed,
Justin Im,
Deok Ryun Kim,
Birkneh Tilahun Tadesse,
Tasnuva Ahmed,
Asma Binte Aziz,
Masuma Hoque,
Juyeon Park,
Xinxue Liu,
Gideok Pak,
Khalequ Zaman,
Florian Marks,
Jerome H. Kim,
John D. Clemens,
Firdausi Qadri
Affiliations
Abdur Razzaque Sarker
Population Studies Division, Bangladesh Institute of Development Studies (BIDS), Bangladesh; Health Economics Unit, University of Birmingham, Birmingham, United Kingdom
Ashraful Islam Khan
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh; Corresponding author at: International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Md. Taufiqul Islam
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Fahima Chowdhury
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Farhana Khanam
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Sophie Kang
International Vaccine Institute, Seoul, Republic of Korea
Faisal Ahmmed
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Justin Im
International Vaccine Institute, Seoul, Republic of Korea
Deok Ryun Kim
International Vaccine Institute, Seoul, Republic of Korea
Birkneh Tilahun Tadesse
International Vaccine Institute, Seoul, Republic of Korea; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden; Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia
Tasnuva Ahmed
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Asma Binte Aziz
International Vaccine Institute, Seoul, Republic of Korea
Masuma Hoque
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Juyeon Park
International Vaccine Institute, Seoul, Republic of Korea; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0AW, United Kingdom
Xinxue Liu
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, United Kingdom
Gideok Pak
International Vaccine Institute, Seoul, Republic of Korea
Khalequ Zaman
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Florian Marks
International Vaccine Institute, Seoul, Republic of Korea; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0AW, United Kingdom; University of Antananarivo, Antananarivo, Madagascar; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany
Jerome H. Kim
International Vaccine Institute, Seoul, Republic of Korea
John D. Clemens
International Vaccine Institute, Seoul, Republic of Korea; UCLA Fielding School of Public Health, Los Angeles, CA 90095-1772, USA
Firdausi Qadri
International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Cholera poses a substantial health burden in the developing world due to both epidemic and endemic diseases. The World Health Organization recommends oral cholera vaccines for mass vaccination campaigns in addition to traditional prevention practices and treatments in resource-poor settings. In many developing countries like Bangladesh, the major challenge behind implementing mass vaccination campaigns concerns the affordability of the oral cholera vaccine (OCV). Vaccination of children with OCV is not only an impactful approach for controlling cholera at the population level and reducing childhood morbidity but is also considered more cost-effective than vaccinating all ages. The aim of the study was to estimate the cost of an OCV campaign for children from a societal perspective using empirical study. A total of 66,311 children aged 1 to 14 years old were fully vaccinated with two doses of the OCV Shanchol while 9,035 individuals received one dose of this vaccine. The estimated societal cost per individual for full vaccination was US$ 6.11, which includes the cost of vaccine delivery estimated at US$ 1.95. The cost per single dose was estimated at US$ 2.86. The total provider cost for full vaccination was estimated at US$ 6.01 and the recipient cost at US$ 0.10. Our estimation of OCV delivery costs for children was relatively higher than what was found in a similar mass OCV campaign for all age groups, indicating that there may be additional cost factors to consider in targeted vaccine campaigns. This analysis provides useful benchmarks for the possible costs related to delivery of OCV to children and future OCV cost-effectiveness models should factor in these possible cost disparities. Attempts to reduce the cost per dose are likely to have a greater impact on the cost of similar vaccination campaigns in many resource-poor settings.